Cardioprotective effects of eplerenone in the rat heart: Interaction with locally synthesized or blood-derived aldosterone?

Hypertension

Volumn 47, Issue 4, 2006, Pages 665-670

  Chai, Wenxia ^a   Garrelds, Ingrid M ^a   De Vries, René ^a   Danser, A H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Arrythmia; Blood flow; Ischemia; Mineralocorticoids

Indexed keywords

ALDOSTERONE; EPLERENONE; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; DRUG DERIVATIVE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HEART ARRHYTHMIA; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; INOTROPISM; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; ANIMAL; BLOOD; DRUG ANTAGONISM; DRUG INTERACTION; HEART; HEART MUSCLE; HEMODYNAMICS; IN VITRO STUDY; KINETICS; METABOLISM; PATHOLOGY; WISTAR RAT;

ALDOSTERONE; ANIMALS; CARDIOTONIC AGENTS; DRUG INTERACTIONS; HEART; HEMODYNAMIC PROCESSES; KINETICS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RATS; RATS, WISTAR; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 33645816102     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000205831.39339.a5     Document Type: Article

References (29)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
2. Pitt B, Remme WJ, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, Rover A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033.
4. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:1800-1807.
5. Beck L, Blanc-Guillemaud V, Cherif OK, Jover B, Davy JM. Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. Cardiology. 2001;96:85-93.
6. Caballero R, Moreno I, Gonzalez T, Arias C, Valenzuela C, Delpon E, Tamargo J. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation. 2003;107:889-895.
7. Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JMJ, Danser AHJ. Genomic and non-genomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol. 2005;145:664-671.
8. Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M, Myoishi M, Okuda H, Ogai A, Okada K, Tsukamoto O, Koyama H, Hori M, Kitakaze M. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension. 2005;46:113-117.
9. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AH. Nongenomic effects of aldosterone in the human heart. Interaction with angiotensin II. Hypertension. 2005;46:701-706.
10. Barbato JC, Mulrow PJ, Shapiro JI, Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension. 2002;40:130-135.
11. Silvestre JS, Heymes C, Oubénaïssa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-2701.
12. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension. 2000;36:495-500.
13. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology. 2004;145:4796-4802.
14. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565.
15. Nakamura S, Yoshimura M, Nakayama M, Ito T, Mizuno Y, Harada E, Sakamoto T, Saito Y, Nakao K, Yasue H, Ogawa H. Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation. 2004;110:1787-1793.
16. Kubasik NP, Warren K, Sine HE. Evaluation of a new commercial radioassay kit for aldosterone using an iodinated tracer. Clin Biochem. 1979;12:59-61.
17. de Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978;235:E97-E102.
18. Barbato JC, Rashid S, Mulrow PJ, Shapiro JI, Franco-Saenz R. Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension. 2004;44:751-757.
19. Tillmann HC, Schumacher B, Yasenyev O, Junker M, Christ M, Feuring M, Wehling M. Acute effects of aldosterone on intracardiac monophasic action potentials. Int J Cardiol. 2002;84:33-40.
20. Mazak I, Fiebeler A, Müller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800.
21. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem. 1998;273:4883-4891.
22. van Kats JP, van Meegen JR, Verdouw PD, Duncker DJ, Schalekamp MA, Danser AH. Subcellular localization of angiotensin II in kidney and adrenal. J Hypertens. 2001;19:583-589.
23. de Lannoy LM, Danser AH, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MA. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension. 1997;29:1240-1251.
24. de Lannoy LM, Schuijt MP, Saxena PR, Schalekamp MA, Danser AH. Angiotensin-converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of isolated perfused rat heart. J Hypertens. 2001;19:959-965.
25. de Lannoy LM, Danser AHJ, Bouhuizen AMB, Saxena PR, Schalekamp MADH. Localization and production of angiotensin II in the isolated perfused rat heart. Hypertension. 1998;31:1111-1117.
26. Danser AH, van Kats JP, Admiraal PJ, Derkx FH, Lamers JM, Verdouw PD, Saxena PR, Schalekamp MA. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension. 1994;24:37-48.
27. Saris JJ, Derkx FHM, de Bruin RJA, Dekkers DHW, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser AHJ. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol. 2001;280:H1706-H1715.
28. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Müller DN. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005;111:3087-3094.
29. Katada J, Meguro T, Saito H, Ohashi A, Anzai T, Ogawa S, Yoshikawa T. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation. 2005;111:2157-2164.